Index 
 Previous 
 Next 
 Full text 
Procedure : 2018/2185(DEC)
Document stages in plenary
Document selected : A8-0135/2019

Texts tabled :

A8-0135/2019

Debates :

PV 26/03/2019 - 12
CRE 26/03/2019 - 12

Votes :

PV 26/03/2019 - 13.30
Explanations of votes

Texts adopted :

P8_TA(2019)0271

Debates
Wednesday, 27 March 2019 - Strasbourg Revised edition

11.2. Discharge 2017: European Medicines Agency (EMA) (A8-0135/2019 - Petri Sarvamaa)
Video of the speeches
 

Dichiarazioni di voto orali

 
  
MPphoto
 

  Alex Mayer (S&D). – Mr President, the GBP 500 million bill because the European Medicines Agency (EMA) could not get out of the 25—year lease on a building in Canary Wharf is deeply regrettable. What a waste. And, to my mind, what a waste to lose highly skilled jobs and research capacity from Britain. The EMA is a jewel in the crown, precisely because it attracts businesses and experts. Over the past two decades, it has been invaluable, simplifying and streamlining medicines regulation, allowing companies to get a medicine authorised in every EU country in one go. Alas for Britain, no more.

A medicines manufacturer in my constituency has already set up a new parallel testing facility within the EU to enable it to sell into European Union countries in the future. More cost, meaning less investment in research and development, and for Britain more delays in getting medicines and a rising bill for medicines, and so less money for our NHS – the opposite of what people thought that they were voting for.

 
Last updated: 28 June 2019Legal notice